99.9% Febuxostat
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- febuxostat
- Category
- Organic Intermediate
Medichemkorea, Co., Ltd
- Verified Certificate
-
11
Product name | 99.9% Febuxostat | Certification | - |
---|---|---|---|
Category | Organic Intermediate | Ingredients | - |
Keyword | febuxostat | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | Stock | - | |
Supply type | - | HS code | - |
Product Information
* Quality of Febuxostat is as under.
B2B Trade
Price (FOB) | Negotiable | transportation | - |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Cho, DongOck
- Address
- #1306, Shinil IT Uto, LS-Ro 13, Gunpo-Si, Gyeonggi-Do, Korea
- Product Category
- Beauty & Personal Care,Industrial Supplies
- No. of Total Employees
- 1-50
- Company introduction
-
"Beyond the dream, above the vision"
Established in 2006, Medichem Korea Co., LTD is a fast growing pharmaceutical company, headquartered in Suwon-Si, Gyeonggi-Do in Korea.
We research, develop, and provide high quality pharmaceuticals in the areas of API's, fine chemicals, new materials, and cosmeceuticals.
We credit our competitive core competency to the investment on R & D and strong manpower.
We have invested about 50% of the revenue for research and development expenses, which led to the development of highly competitive and value added products.
Of course, all of this is made possible by the people of MediChem Korea and their strong commitments as researchers. Our researchers are all ph.D holders and have extensive experiences in R & D.Medichem Korea has pursued excellence on every aspect of process since its establishment in March of 2006 and finally, our company has succeeded in developing four types of blockbuster generics such as atorvastatin (anti-hypertensive ;HMG Co A reductase), meropenem (antibiotics; cabapenem), Montelukast (except asthma treatment), and cosmectics (whitening, anti-wrinkles, UV-screening).
As a result of dedicated endeavors in R & D, Medichem Korea has produced highly value added products and laid the cornerstone for a strong pharmaceutical company around the world with new technologies.
With the vision of emerging as a leading pharmaceutical company both in domestic and overseas markets, Medichem Korea will make continuous efforts to search for new products and improve current products and thereby enhance people’s quality of life.- API's
Preoccupy the 1st generic markets through the development of core intermediates of raw material medicines and API's, which are highly marketable blockbuster products.
Finished products: anti hypertensive agents, asthma treatments, rheumatism treatments, antibiotics, etc.
Products on intermediate: asthma treatments, antibiotics, anti-cancer agents, diabetes treatments, etc.- Secure high value added products through the development of core intermediates
- Secure production competitiveness through the production outsourcing of raw material medicines
- Expand added value through licensing raw material medicines to domestic/global pharmaceutical companies- Fine Chemicals
- Develop high value-added stereochemical substances
- Develop customer centered and high value-added chemical substances- New Materials
- Research and develop organic/inorganic chemical substances, which are useful for electrics and electronics
- Research and develop Nano synthetic chemical substances
- Research and develop customer centered chemical substances- Cosmetics
- Research and develop anti-wrinkles, whitening cosmetics, UV-screening substances, etc.
- Develop raw materials of cosmetic ingredients based on customer’s needs
- Main Markets
-
Japan
South Korea
Taiwan
- Main Product